Senti Biosciences Holdings, Inc. Common Stock (SNTI) is a publicly traded Healthcare sector company. As of May 21, 2026, SNTI trades at $0.95 with a market cap of $29.28M and a P/E ratio of -0.35. SNTI moved +7.91% today. Year to date, SNTI is -13.27%; over the trailing twelve months it is -69.38%. Its 52-week range spans $0.77 to $16.94. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces SNTI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Senti Biosciences Secures $40M Financing, Advances SENTI-202 Pivotal AML Trial: First quarter net loss fell to $4.2 million from $14.1 million year-over-year as cash burn halved to $7.5 million, underpinned by a $6.9 million lease-modification gain and streamlined operations. The company secured up to $40 million in convertible-note financing and received FDA feedback endorsing a single-arm pivotal trial for SENTI-202 in R/R AML.
| Metric | Value |
|---|---|
| Price | $0.95 |
| Market Cap | $29.28M |
| P/E Ratio | -0.35 |
| EPS | $-2.73 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.94 |
| 52-Week Low | $0.77 |
| Volume | 21 |
| Avg Volume | 0 |
| Revenue (TTM) | $22.00K |
| Net Income | $-61.44M |
| Gross Margin | 0.00% |
1 analysts cover SNTI: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.00.